Markets:

Overview

News

Currencies

International

Treasuries

Allurion Technologies, Inc. Common Stock (NY:ALUR)

1.858 +0.768 (+70.47%)

Streaming Delayed Price Updated: 1:46 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Allurion Technologies, Inc. Common Stock

< Previous 1 2 3 4 Next >

Allurion Receives U.S. FDA Approval

Today 9:00 EST

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

February 03, 2026

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

January 12, 2026

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

November 25, 2025

From Allurion Technologies, Inc.

Via Business Wire

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

November 20, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

November 18, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

November 11, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025

November 06, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss

October 07, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

September 30, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

August 07, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

August 05, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program

July 22, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

July 09, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

July 07, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

June 17, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Present at Jefferies Global Healthcare Conference

May 29, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program

May 27, 2025

From Allurion Technologies, Inc.

Via Business Wire

Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside

May 14, 2025

Via AB Newswire

Topics Artificial Intelligence

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

May 13, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

May 05, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Postponement of Special Meeting of Stockholders

April 03, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

March 26, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence

March 20, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025

March 12, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity

March 04, 2025

From Allurion Technologies, Inc.

Via Business Wire

Allurion to Participate in Upcoming Investor Conferences

February 25, 2025

From Allurion Technologies, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.